Previous 10 | Next 10 |
Takung Art (TKAT) +81%.Evolus (EOLS) +43% after company updates on U.S. ITC case related to Jeuveau sales and marketing.Skillful Craftsman Education Technology (EDTK) +17%.Marathon Patent Group (MARA) +23%.Rite Aid Corporation (RAD) +21% on Q3 results.Vivos Therapeuti...
Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carryi...
Gainers: Ever-Glory International (EVK) +260%.Lizhi (LIZI) +89%.Nesco Holdings (NSCO) +60%.Waddell & Reed Financial (WDR) +50%.Enlivex Therapeutics (ENLV) +36%.Priority Technology (PRTH) +35%.Aemetis (AMTX) +24%.Zscaler (ZS) +24%.Aehr Test Systems (AEHR) +24%.Arlo Technologies (...
Gainers: Enlivex Therapeutics (ENLV) +24%, Cellectar Biosciences (CLRB) +18%, Omeros (OMER) +15%, Trxade Group (MEDS) +13%, AlloVir (ALVR) +10%.Losers: ReWalk Robotics (RWLK) -11%, Precision BioSciences (DTIL) -11%, Merrimack Pharmaceutic...
Enlivex Therapeutics (ENLV) jumps 35% in premarket, in reaction to announcement of interim data from Phase 2 trial evaluating Allocetra in severe/critical COVID-19 patients. Interim results relate to eight patients, six of whom were in severe condition and two of whom were in c...
Phoenix New Media (FENG) +115%.Lizhi (LIZI) +97% on collaboration with Xpeng MotorsEver-Glory International Group (EVK) +85%.Nesco Holdings (NSCO) +51% after announcing acquisition of Custom Truck One Source for $1.475B.Cyanotech Corporation (CYAN) +42%.Waddell & Reed Financial ...
Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of an investigator-initiated Phase II clinical trial evaluating Allocetra TM in sev...
* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options * Nes Ziona, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a...
* Dr. Schwartz Served as ArQule’s Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 * Nes Ziona, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the ...
Nes Ziona, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs d...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...